DSIJ Mindshare

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

Ashwin Urkude 0 265 Article rating: 3.7

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

Maximize Your Investment Potential with This Small Cap Fund

In this article, you will discover the top five mutual funds that delivered the highest returns in the past year, followed by an in-depth analysis of one of these funds.

Ashwin Urkude 0 424 Article rating: 4.3

In this article, you will discover the top five mutual funds that delivered the highest returns in the past year, followed by an in-depth analysis of one of these funds.

RSS
1345678910Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR